Scientific publications

Is immunotherapy here to stay in multiple myeloma?

Mar 1, 2017 | Magazine: Haematologica

Rodríguez-Otero P (1), Paiva B (1), Engelhardt M (2), Prósper F (1), San Miguel JF (3). (1) Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
(2) Department of Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Germany.
(3) Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain 


ABSTRACT

Immune escape and impaired immune surveillance have been identified as emerging hallmarks of cancer.

Multiple myeloma represents a genuine example of disrupted immune surveillance characterized by: impaired antibody production, deregulation of the T and natural killer cell compartment, disruption of antigen presentation machinery, upregulation of inhibitory surface ligands, and recruitment of immunosuppressive cells.

Although the potential value of immunotherapeutic interventions had a clear antecedent in the graft-versus-myeloma effect induced by allogeneic stem cell transplant and donor lymphocyte infusions, it is only recently that this field has faced a real revolution.

In this review we discuss the current results obtained with immune approaches in patients with multiple myeloma that have placed this disease under the scope of immuno-oncology, bringing new therapeutic opportunities for the treatment of multiple myeloma patients.

CITATION  Haematologica. 2017 Mar;102(3):423-432. doi: 10.3324/haematol.2016.152504. Epub 2017 Jan 12.

Our authors

Navarre headquarters
Madrid headquarters